Audentes Therapeutics, Inc. (BOLD) Major Shareholder Sells $111,750.00 in Stock
Audentes Therapeutics, Inc. (NASDAQ:BOLD) major shareholder Orbimed Advisors Llc sold 5,000 shares of Audentes Therapeutics stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $22.35, for a total value of $111,750.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Shares of Audentes Therapeutics, Inc. (NASDAQ:BOLD) opened at 24.30 on Thursday. The firm has a 50-day moving average of $24.32 and a 200 day moving average of $18.10. Audentes Therapeutics, Inc. has a 1-year low of $13.13 and a 1-year high of $24.87. The stock’s market capitalization is $675.15 million.
Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.10). On average, equities analysts anticipate that Audentes Therapeutics, Inc. will post ($3.53) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/14/audentes-therapeutics-inc-bold-major-shareholder-sells-111750-00-in-stock.html.
A number of hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System lifted its stake in Audentes Therapeutics by 128.8% during the second quarter. California State Teachers Retirement System now owns 27,000 shares of the biotechnology company’s stock valued at $517,000 after purchasing an additional 15,200 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Audentes Therapeutics by 1,086.0% during the second quarter. The Manufacturers Life Insurance Company now owns 13,580 shares of the biotechnology company’s stock valued at $260,000 after purchasing an additional 12,435 shares during the last quarter. Redmile Group LLC lifted its stake in Audentes Therapeutics by 77.8% during the second quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock valued at $27,922,000 after purchasing an additional 638,780 shares during the last quarter. State Street Corp lifted its stake in Audentes Therapeutics by 231.6% during the second quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock valued at $4,234,000 after purchasing an additional 154,544 shares during the last quarter. Finally, OxFORD Asset Management LLP acquired a new stake in Audentes Therapeutics during the second quarter valued at approximately $428,000. 77.01% of the stock is owned by institutional investors and hedge funds.
Several brokerages recently issued reports on BOLD. ValuEngine upgraded Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. Evercore ISI began coverage on shares of Audentes Therapeutics in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 target price for the company. Finally, Zacks Investment Research cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $22.40.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.